Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients.

Jamalizadeh, Mahdieh; Hasanzad, Mandana; Sarhangi, Negar; Sharifi, Farshad; Nasli-Esfahani, Ensieh; Larijani, Bagher

Jamalizadeh, Mahdieh; Hasanzad, Mandana; Sarhangi, Negar; Sharifi, Farshad; Nasli-Esfahani, Ensieh; Larijani, Bagher.

Afiliación

Jamalizadeh M; Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Hasanzad M; Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Sarhangi N; Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Sharifi F; Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Nasli-Esfahani E; Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Larijani B; Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

J Diabetes Metab Disord ; 20(2): 1407-1413, 2021 Dec.

Article en En | MEDLINE | ID: mdl-34900792

Palabras clave

Empagliflozin; SGLT2 inhibitor; SLC5A2; Type 2 diabetes mellitus; rs11646054

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Diabetes Metab Disord Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google